| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -95.7 | -39.6 |
| EPS (diluted, $ a share) | $-0.74 | $-39,623.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KLRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kailera Therapeutics, Inc.: key numbers
- Share price
- $12.57Close, Nov 16
- Market cap
- $1.63B
- Shares outstanding
- 129.85MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kailera Therapeutics, Inc.
All →Kailera Therapeutics Financial Results
Kailera Therapeutics reported Q3 2026 financial results, ending the period with $847.4 million in cash and equivalents to support operations into mid-2028. The company highlighted significant clinical progress, including the full enrollment of its KaiNETIC Phase 3 program for injectable ribupatide and plans to initiate a Phase 3 program for oral ribupatide in 1H 2027.
- Term
- Q3 2026
“Kailera was built to bring new medicines to people living with obesity, and our strong execution this quarter reflects that commitment. All four of our product candidates are on track to deliver important clinical milestones in 2027, including the initiation of our Phase 3 trial for ribupatide oral and the data readout from the ribupatide injection high-dose Phase 2b trial. With the ribupatide franchise’s category-leading potential at the core of a diversified portfolio, and a balance sheet that supports multiple value-creating inflection points into mid-2028, I am proud of our team and energized by what we aim to deliver for people living with obesity.”
Ron Renaud, President and Chief Executive Officer of Kailera